Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.
Syed Rizvi, MD
Advertisement
Articles by Syed Rizvi, MD
Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.
Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.
Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses treatment considerations in stage III/IV Hodgkin lymphoma.
Advertisement
Latest Updated Articles
Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin LymphomaFebruary 11th 2020
Dr. Rizvi on the Limitations of ABVD in Hodgkin LymphomaApril 24th 2020
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
3
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5